

#### IRB Approval – Expedited Review of New Study

To: Chad Hall

**Date:** July 18, 2024

**Re:** 024-352

Skin Closure After Infected Laparotomy (SCAIL): An EAST Multicenter

Trial

Reference Number: 403260

Your new proposal was reviewed by a designated member of Baylor Scott & White Research IRB Red via expedited review.

This study was determined to be eligible for expedited review as it involves no greater than minimal risk to the subjects and fits into the following category from the 1998 approved list: Category 5: Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis)

This review included the following components:

This review included the following components.						
Submission Components						
Form Name		Version	Outcome			
Review Response Submission Form		Version 2.0	Approved			
Review Response Submission Form		Version 1.0	Approved			
Initial Review Submission Packet		Version 1.1	Approved			
Study Application - Review by BSWRI IRB		Version 1.2	Approved			
Study Document						
Title	Version #	<b>Version Date</b>	Outcome			
EAST_Wound_management_protocol_V5	Version 1.0	n/a	Approved			
K121883	Version 1.0	06/26/2024	Acknowledged			
SCAIL data_dictionary_v1	Version 1.0	06/26/2024	Acknowledged			
SCAIL data_collection_tool-v1	Version 1.0	06/26/2024	Acknowledged			

Your submission has been approved. The approval period begins on 7/18/2024 and expires on 7/17/2025. Your next continuing review is scheduled for 6/17/2025.

This study is approved to be conducted at the following locations: Scott & White Clinic - Temple

The following individuals are approved as key study personnel or are acknowledged as study contacts/administrative support/department approvers: Hall, Chad; Lal, Sohan; Vargas, Richard

**Waiver of consent/authorization**: The IRB has waived the requirement for informed consent based on 45 CFR 46.116 (f). The IRB has 1) waived the requirement for authorization based on 45 CFR 164.512 (i) (2) (ii) and 2) determined the use of existing protected health information is necessary to do the research.

All events that occur on this study including protocol deviations, serious adverse events, unanticipated problems involving risks to subjects/others, subject complaints or other similar events must be reported to the IRB in accordance with the respective policies.

Remember that this study is approved to be conducted as presented. Any revisions to this proposal and/or any of the referenced documents must be approved by the IRB prior to being implemented. Additionally, if you wish to begin using any new documents, these must receive IRB approval prior to implementation of them in the study.

IRB approval may not be the final approval needed to begin the study. All contractual, financial or other administrative issues must be resolved through Baylor Scott & White Research Institute prior to beginning your study.

For Investigator Initiated studies that meet the requirements to be posted on <a href="www.clinicaltrials.gov">www.clinicaltrials.gov</a>; as Principal Investigator, it is your responsibility to ensure that your study is listed prior to enrolling the first subject. Instructions on fulfilling this requirement can be found in iRIS under the "Help" tab.

If you need additional assistance, please contact the IRB Specialist at 254-215-9697.

Sincerely,

Lam Cli

Signature applied by Lauren Ellis on 07/18/2024 03:40:17 PM CDT



# Eastern Association for the Surgery of Trauma Advancing Science, Fostering Relationships, and Building Careers

### **EAST MULTICENTER STUDY DATA COLLECTION TOOL**

Multicenter Study:Sk	kin Closure After Infec	ted Laparotomy (SCAIL)_	
Enrolling Center: Enrolling Co-investigator:			
Initial Demographics / In	njury Variables:		
Age:(\ge 18)	Gender: (M/F) cimals)	Date of Initial Laparotomy	: (MM/DD/YYYY)
Liver disease Chronic kidney disease Chronic steroid use Congestive heart failure Coronary artery disease OSA/COPD CVA/TIA Cancer Chemotherapy Active smoker	YES/NO YES/NO YES/NO		
Laparotomy Indication: Trauma Emergency Gene If Trauma, Mechanism of Blunt: Penetrating:  ISS:(N/AIS Abdomen:	<u>initial injury:</u> YES / NO YES / NO A, 0-75) AIS Head: _	(0-5) AIS Chest:	(0-5)
Obstruction \ Perforation	g <u>ery:</u> Yes/No Yes/No Yes/No Yes/No		

Admission Lab values:				
Hemoglobin: (No decimals) pH: (2 decimals) INR: (1 decimal) Lactate: (1 decimal) Base Deficit: (+ or -, no decimals)				
Intra-operative variables:				
Wound Class: III/IV ASA Class: (1-5) Estimated blood loss: (mL) Highest intra-op temperature (Celsius): (one decimal) Any temperature <35C: YES/NO Wound protector used: YES/NO Intra-operative vasopressor therapy: YES/NO Intra-operative antibiotics given: YES/NO (Type:) Stoma created: YES/NO				
Intra-operative resuscitation:				
Intra-operative crystalloid given: Total Intra-operative blood products given: PRBC volume: FFP volume: Platelet volume:  Intra-operative non-blood colloid given:  mL  mL  mL				
Total fluid balance from OR mL				
Management of Fascia  Fascia closed during primary operation YES/NO  If NO, indication for use of open abdominal management (check one that best applies)  Damage control  To facilitate early re-exploration and urgent/emergent re-evaluation (i.e. assessment of bowel viability or ongoing contamination)  Decompression of abdomen in setting of elevated ICP  Other:				
Date of fascial closure: (MM/DD/YYYY)				
Number of planned reoperations (takebacks):				
Fascial closure method (check one that best applies):  running looped monofilament suture  running single arm monofilament suture  interrupted monofilament suture  running braided suture  running barbed suture				
Was mesh (biologic, biosynthetic, or synthetic) utilized for fascial closure reinforcement: YES/NO				
What was the type of skin closure utilized (Check one)?  Skin left open, heal by secondary intention				

Post-operative course:  Were IV or oral antibiotics utilized post-operatively (circle one): YES/NO  If yes, duration of antibiotics after initial laparotomy (days):  Were IV or oral antifungals utilized post-operatively (circle one): YES/NO  If yes, duration of antifungals after initial laparotomy (days):	
Total MMEs given during hospitalization (excluding continuous infusions): Total MMEs given during last 24 hours of hospitalization (excluding continuous infusions):	
Outcomes:	
Surgical Site Infection within 30 days: YES/NO	
If Yes (Check one that best applies),  Superficial, Days from initial laparotomy:  Deep, Days from initial laparotomy:  Organ space, Days from initial laparotomy:	
Results of Fascial Closure: (check as applies)  No complication Re-exploration required for: Abdominal compartment syndrome Abdominal sepsis Dehiscence / Early repair failure Other:  Wound healed within 30 days of initial operation? YES/NO	
Date of wound closure (staples removed OR vac and/or packing discontinued):(	(MM/DD/YYYY)
Complications: (check all that apply and list Hospital Day encountered)  Fascial dehiscence HD # Enteric fistula HD # Intra-abdominal abscess / sepsis HD #	
Hospital LOS: Ventilator Days: ICU LOS:	
Mortality within 30 days (circle one): YES/NO Discharge Destination:  If Yes, date of mortality: (MM/DD/YYYY) Home: YES/NO Rehab: YES/NO LTAC/SNF: YES/NO	
Date of last follow up: (MM/DD/YYYY) Days from initial laparotomy to last follow up:	



## Eastern Association for the Surgery of Trauma

Advancing Science, Fostering Relationships, and Building Careers

# EAST MULTICENTER STUDY DATA DICTIONARY

Incisional Vac after Contaminated Laparotomy (ICLap) - Data Dictionary

Data Entry Points and appropriate definitions / clarifications:

Entry space Definition / Instructions

#### **Standard Study Questions**

Laparotomy Date Date of initial Laparotomy

Age Age of patient enrolled

#### **Case Information**

Gender Gender of Patient enrolled

BMI Body mass index

Diabetes Mellitus Type I or type II diabetes mellitus Liver disease Documented history of cirrhosis

Chronic kidney disease Dialysis dependent

Chronic steroid use Daily steroid use within the past 30 days

Congestive heart failure Documented history of heart failure with/without preserved ejection

fraction

Coronary artery disease History of myocardial infarction, percutaneous coronary intervention or

CABG

OSA/COPD History of obstructive sleep apnea or chronic obstructive pulmonary

disease

Cancer Known active malignancy

Chemotherapy Treated with chemotherapy and/or biologic therapy within 30 days

Active smoker Daily tobacco use within 30 days

Albumin <3 Albumin obtained on admission prior to initial laparotomy

#### **Mechanism of initial Injury**

Blunt Single choice for best description of blunt

mechanism (if penetrating mechanism proceed to

next data point) Options include:

MVC,

Auto vs. Peds (Pedestrian),

Fall, Assault,

MCC (Motorcycle Collision / Crash)

Machinery Other Penetrating Single choice for best description of penetrating

mechanism. Options include: GSW (Gunshot wound) Shotgun (Shotgun wound) Stab (Stab Wound)

Other

ISS Numerical value for calculated ISS

(ISS = Injury Severity Score)

AIS Head Numerical Value for AIS body region = Head

(AIS = Abbreviated Injury Score)

AIS Chest Numerical Value for AIS body region = Chest

(AIS = Abbreviated Injury Score)

AIS Abdomen Numerical Value for AIS body region = Abdomen

(AIS = Abbreviated Injury Score)

#### Pre-Operative Lab Values

Hemoglobin Most recent Hemoglobin value (g/dL)

pH Most recent pH value (arterial preffered, but venous

venous value acceptable if no arterial value

available)

Lactate Most recent lactate (mmol/L)

Base Deficit Most recent Base Deficit (mmol/L)

#### **Intra-operative Variables**

Wound Class III or IV only, see protocol

ASA Class 1- healthy, 2- mild systemic disease, 3- severe systemic disease, 4-

severe systemic disease that is a constant threat to life, 5- moribund

patient who is not expected to survive

Estimated blood loss Blood loss from initial laparotomy in mL

Highest intra-op temperature Highest core temperature during initial laparotomy in Celsius

Any Temp <35C <35C at any time during initial laparotomy

Wound protector used Ringed wound protector used during initial laparotomy Vasopressor therapy norepinephrine, phenylephrine, vasopressin, or epinephrine

Antibiotics given During initial laparotomy

Stoma created colostomy or ileostomy, loop or end

#### **Intra-operative Resuscitation**

Intra-operative crystalloid

given (mL)

Recorded intra-operative crystalloid given (in mL's)

PRBC volume (mL) PRBC (Packed Red Blood Cells) administered

during the initial operation (in mL's)

FFP volume (mL) FFP (Fresh Frozen Plasma) administered

during the initial operation (in mL's)

Platelet volume (mL) Platelet volume administered during

the intitial operation (in mL's)

Total intra-operative blood

products given (mL)

Total intra-operative blood products given

during the initial operation (PRBC, FFP, Platelets,

cryoprecipitate) (in mL's)

Intra-operative non-blood

colloid given (mL)

Total intra-operative non-blood colloid given during the initial operation (albmumin, hespan

hextend or other colloid) (in mL)

Total fluid balance from OR Total fluid administered (crystalloid, blood product,

and colloid) – intra-operative blood loss (in mL). If a negative number annotate with a negative (-) sign

#### Damage control indicators present during operation

Clinical coagulopathy Clinical (not laboratory) assessment of clinical

coagulopathy during initial operation (persistent non-surgical bleeding, etc.) – Check if present

Acidosis Acidosis defined as pH <7.35 during operation

Check if present

Lowest pH Lowest recorded pH during operation – Free text

entry of value.

Hypothermia (defined as intra-operative

Temperature < 35.0 Celsius) – Check if present

**Management of Fascia** 

Fascial closure Definitive closure of abdominal fascia with suture

Planned reoperations Number of planned laparotomy re-openings after initial operation

(takebacks)

**Skin Closure** 

Secondary intention Skin left open with or without negative pressure wound vac therapy

Incisional vac Skin closed with staples, negative pressure vac placed over staples

**Post-operative Course** 

Antibiotic duration Consecutive days from date of initial laparotomy

Antifungal duration Consecutive days from date of initial laparotomy

MMEs Morphine milligram equivalents

#### **Outcomes**

Surgical site infection Within 30 days from initial laparotomy; superficial/deep/organ space- see

protocol for definitions of each

Re-exploration Unplanned return to the OR for re-opening of laparotomy

Dehiscence Spontaneous fascial opening after closure

Wound healed Staple removal in closed incisions OR complete discontinuation of vac

and packing material in open wounds

Enteric fistula Spontaneous communication of GI tract to skin level with drainage of

enteric contents through wound or skin

Intra-abdominal abscess Identified by radiologic evaluation or intra-operative exploration

Hospital LOS (days) Free text entry for number of consecutive days

patient hospitalized at initial admission (Day

of admission = hospital day #1) LOS = Length of Stay

ICU LOS (days)

Free text entry of number of consecutive days

patient required ICU admission (ICU = Intensive Care Unit, LOS = Length of Stay) - Day of

admission = hospital day #1

Ventilator days Free text entry for total number of days patient

required mechanical ventilation (Day of admission = hospital day #1)

Mortality Drop down menu. Yes or No. Did patient expire within 30 days of

admission?

Discharge Destination If alive: home, inpatient rehabilitation center, long term acute care/skilled

nursing facility